Search results for "imidazoles"

showing 10 items of 272 documents

The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: The SURGE 2 practice-based study

2013

SURGE 2, a large-scale, practice-based study in 10 countries, evaluated the effects of telmisartan alone or with hydrochlorothiazide (HCTZ) on morning (06:00 – 11:59) home blood pressure (HBP) control. Hypertensive patients (clinic blood pressure [BP] 140/90 mmHg) received telmisartan 40 or 80 mg either alone or in combination with HCTZ 12.5 mg for 8 weeks. Treatment could be adjusted if clinic BP remained 140/90 mmHg. Clinic BP was measured in the morning prior to medication, and seated HBP monitoring was performed, three times per day, 2 days per week. A total of 25,882 patients were included (71% were previously using antihypertensives). There was a statistically signifi cant (all p 0.00…

AdultMalemedicine.medical_specialtyEveningAdolescentDiastoleBlood PressureBenzoatesYoung AdultHydrochlorothiazideInternal medicineInternal MedicinemedicineHumansProspective StudiesTelmisartanProspective cohort studyAdverse effectAntihypertensive AgentsMorningAgedAged 80 and overbusiness.industryHome blood pressure monitoring hydrochlorothiazide morning blood pressure control telmisartanGeneral MedicineMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedDrug CombinationsEndocrinologyBlood pressureHydrochlorothiazideAnesthesiaHypertensionBenzimidazolesFemaleTelmisartanCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockersmedicine.drug
researchProduct

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis

2014

Background— Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings. Methods and Results— In a randomized, double-blind, double-dummy trial of 2589 patients with acute VTE treated with low-molecular-weight or unfractionated heparin for 5 to 11 days, we compared dabigatran 150 mg twice daily with warfarin. The primary outcome, recurrent symptomatic, objectively confirmed VTE and related deaths during 6 months of treatment occurred in 30 of the 1279 dabigatran patients (2.3%) compared with 28 of the 1289 warfarin patients (2.2%; hazard ratio, 1.08; 95% confidence interval [CI], 0.…

AdultMalemedicine.medical_specialtyRE-COVER IIrecurrenceAntagonists & inhibitorsAdolescentvenous thromboembolismAntithrombinsDabigatranYoung AdultDouble-Blind MethodRisk FactorsPhysiology (medical)Internal medicinemedicineHumansdabigatrancardiovascular diseasesantagonists & inhibitorAgedacute venous thromboembolismHeparinbusiness.industryWarfarinFollow up studiesAnticoagulantsantagonists & inhibitors; hemorrhage; recurrence; thrombin; venous thromboembolism; warfarinHeparinHeparin Low-Molecular-WeightMiddle AgedthrombinSettore MED/11 - Malattie Dell'Apparato CardiovascolarewarfarinHeparin.low molecular weightPooled analysisAnesthesiaAcute Diseasebeta-AlanineBenzimidazolesFemaledabigatran; warfarin; acute venous thromboembolism; RE-COVER IIhemorrhageCardiology and Cardiovascular MedicinebusinessVenous thromboembolismFollow-Up Studiesmedicine.drug
researchProduct

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholeste…

2017

Homozygous familial hypercholesterolemia is a genetic disorder characterized by low-density lipoprotein (LDL)-receptor dysfunction, markedly elevated levels of LDL-cholesterol (LDL-C) and premature atherosclerosis. Patients are often poorly responsive to conventional lipid-lowering therapies that upregulate LDL-receptor expression.1 Lomitapide inhibits microsomal triglyceride transfer protein, which lipidates nascent apolipoprotein (apo)B-containing lipoproteins. In a pivotal 78-week open-label trial, lomitapide, titrated to the maximal tolerable dose, decreased LDL-C by 50% at the end of the efficacy phase (week 26) in patients with homozygous familial hypercholesterolemia.2 The principal …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BSocio-culturaleFamilial hypercholesterolemia030204 cardiovascular system & hematologyGastroenterologyMicrosomal triglyceride transfer proteinLDLTimeSudden cardiac deathHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)Internal medicinemedicineHumans030212 general & internal medicineAdverse effectlomitapidebiologybusiness.industryCholesterolAnticholesteremic AgentsCholesterol LDLlomitapide; Adult; Anticholesteremic Agents; Benzimidazoles; Carrier Proteins; Cholesterol LDL; Female; Humans; Hyperlipoproteinemia Type II; Male; Timemedicine.diseaseLomitapideCholesterolEndocrinologychemistrybiology.proteinBenzimidazolesFemalelipids (amino acids peptides and proteins)lomitapide; Cardiology and Cardiovascular Medicine; Physiology (medical)Carrier ProteinsCardiology and Cardiovascular MedicinebusinessLipoproteinCirculation
researchProduct

Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.

2014

The microsomal triglyceride transfer protein (MTP) inhibitor lomitapide is a licenced adjunct to a low-fat diet and other lipid-lowering medication, with or without low-density lipoprotein apheresis, for the treatment of adults with homozygous familial hypercholesterolaemia (HoFH). In a recently published phase 3 study, patients with HoFH received lomitapide in addition to maximally tolerated lipid-lowering therapy. Treatment with lomitapide resulted in a mean approximate 50% reduction in LDL-C levels after 26 weeks compared with baseline levels (p < 0.0001). This decrease in LDL-C was maintained at Weeks 56 and 78 (44% [p < 0.0001] and 38% [p = 0.0001], respectively). This paper offers cli…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaPhases of clinical researchMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type IIchemistry.chemical_compoundYoung AdultInternal medicineHo-FH lomitapide MTPInternal MedicinemedicineEffective treatmentHumansIn patientAdverse effectbiologymedicine.diagnostic_testbusiness.industryAnticholesteremic AgentsHomozygoteGeneral MedicineCholesterol LDLMiddle AgedLomitapideEndocrinologyApheresisTreatment Outcomechemistrybiology.proteinBenzimidazolesFemaleCardiology and Cardiovascular MedicinebusinessLiver function testsAtherosclerosis. Supplements
researchProduct

Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics

1997

AdultMalemedicine.medical_specialtyglossitiGlossitismedicine.drug_classAntibioticsadverse drug reactionLansoprazole2-PyridinylmethylsulfinylbenzimidazolesGlossitisPharmacotherapyTongueClarithromycinClarithromycinmedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)StomatitisAgedStomatitisbusiness.industryMiddle AgedAnti-Ulcer Agentsmedicine.diseaselansoprazoleDermatologyAnti-Bacterial Agentsmedicine.anatomical_structureDrug Therapy CombinationFemalebusinessclarythromicinOmeprazoleAdverse drug reactionmedicine.drug
researchProduct

Effect of intravenous application of esomeprazole 40???mg versus pantoprazole 40???mg on 24-hour intragastric pH in healthy adults

2007

BACKGROUND: It has been demonstrated that therapy with proton pump inhibitors reduces recurrence of bleeding following initial endoscopic treatment of bleeding peptic ulcers. AIM: This study compared the effects of esomeprazole 40 mg and pantoprazole 40 mg on intragastric acid control. Both substances were administered intravenously as 15-min infusion and as bolus injection. METHODS: Healthy men and women volunteers were enrolled in this single-center, open, randomized, three-way crossover study. After administration of esomeprazole 40 mg and pantoprazole 40 mg intravenously as 15-min infusion, and pantoprazole 40 mg intravenously as bolus injection, continuous 24-h intragastric pH monitori…

AdultMalemedicine.medical_specialtymedicine.drug_classPepticProton-pump inhibitorPharmacologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesHelicobacter InfectionsEsomeprazoleGastric AcidInternal medicineHumansMedicineEsomeprazole SodiumInfusions IntravenousPantoprazoleMonitoring PhysiologicPantoprazoleCross-Over StudiesHelicobacter pyloriHepatologybusiness.industryStomachGastroenterologyEsomeprazoleGastric Acidity DeterminationHydrogen-Ion ConcentrationMiddle AgedAnti-Ulcer AgentsCrossover studymedicine.anatomical_structureInjections IntravenousBody ConstitutionGastric acidFemalebusinessmedicine.drugEuropean Journal of Gastroenterology &amp; Hepatology
researchProduct

Nasal airway in cleft-palate patients: acoustic rhinometric data

1997

The objective of this study was to investigate an instrumental assessment technique for acquiring reproducible, metric data on the nasal airway in cleft-palate associated nasal dysplasia. A consecutive sample of 23 unilateral, 17 bilateral CLP patients and 15 controls with subjective normal nasal patency from a cleft-palate rehabilitation centre were studied. A series of transnasal acoustic measurements (pressure wave: 55 dB for 2 ms) of nasal volume were performed before and after topical decongestion with 2 x 0.3 mg of xylometazoline. A standardized regimen of acoustic parameters of the nasal valve and the adjacent segment of the nasal cavity were calculated. The cleft side yielded a sign…

AdultNasal cavitymedicine.medical_specialtyAdolescentCleft Lipmedicine.medical_treatmentNoseRhinoplastyXylometazolineAcoustic rhinometryotorhinolaryngologic diseasesmedicineHumansLongitudinal StudiesChildNosemedicine.diagnostic_testbusiness.industryImidazolesNose Deformities AcquiredReproducibility of ResultsAcousticsHypertrophyrespiratory systemRhinoplastySurgeryCleft PalatePosterior segment of eyeballNasal DecongestantsNasal MucosaSoundmedicine.anatomical_structureOtorhinolaryngologySurgeryNasal CavityNasal ObstructionOral SurgeryRhinomanometryAirwaybusinessFollow-Up Studiesmedicine.drugJournal of Cranio-Maxillofacial Surgery
researchProduct

Efficacy and safety of lomitapide in familial chylomicronaemia syndrome

2022

Familial chylomicronaemia syndrome (FCS) is a rare autosomal recessive disorder, resulting in elevated triglycerides (TGs), abdominal pain and pancreatitis. Treatment options are limited. Lomitapide, a microsomal triglyceride transfer protein inhibitor, is approved for the treatment of homozygous familial hypercholesterolaemia. Whether its therapeutic use may be extended to FCS remains unknown. The aim of this study was to evaluate the efficacy and safety of lomitapide in adult patients with FCS.The open-label, single-arm 'LOCHNES' study of lomitapide in FCS enrolled patients18 years with genetically confirmed FCS, elevated fasting TG ≥ 750 mg/dL and history of pancreatitis. Patients were a…

AdultPancreatitiSettore MED/09 - Medicina InternaTriglycerideBenzimidazoleLomitapideAbdominal PainPancreatitisHyperlipoproteinemia Type I.HumansBenzimidazolesHyperlipoproteinemia Type ICardiology and Cardiovascular MedicineTriglyceridesFamilial chylomicronaemia syndromeHuman
researchProduct

Four-phase rhinomanometry: a multicentric retrospective analysis of 36,563 clinical measurements

2015

Rhinomanometry can still be considered as the standard technique for the objective assessment of the ven- tilatory function of the nose. Reliable technical requirements are given by fast digital sensors and modern information technology. However, the xyimaging of the pressure-flow relation typically shows loops as a sign of hysteresis, with the need for resolution of the breath in four phases. The three pillars of 4-phase rhinomanometry (4PR) are the replacement of estimations by measurements, the introduc- tion of parameters related to the subjective sensing of obstruction, and the graphical information regarding the disturbed function of the nasal valve. In a meta-analysis of 36,563 clini…

AdultPercentilemedicine.medical_specialtyVisual Analog ScaleEffective resistanceVisual analogue scaleParameterNoseLogarithmic transformationWhite PeopleXylometazoline03 medical and health sciences0302 clinical medicineStatisticsRetrospective analysismedicineHumans030223 otorhinolaryngologyNosePain MeasurementRetrospective Studiesmedicine.diagnostic_testbusiness.industryAirway ResistanceImidazolesClinical validationGeneral MedicineRhinologyStandard techniqueRhinomanometryNasal DecongestantsMeta-analysismedicine.anatomical_structureOtorhinolaryngologyOtorhinolaryngology030220 oncology & carcinogenesisFour-phase rhinomanometryRegression AnalysisRhinomanometryNasal Obstructionbusinessmedicine.drugEuropean Archives of Oto-Rhino-Laryngology
researchProduct

Acoustic Airway Profiles in Unilateral Cleft Palate Patients

1999

Objective: This study investigates the nasal airway in unilateral cleft palate patients by means of a noninvasive, objective diagnostic method that provides topographic information about the airway profile. Design: A consecutive sample of patients was measured. Setting: Cleft palate rehabilitation center of the University of Mainz, Germany. Patients: Forty-nine subjects were investigated: 34 full-grown patients with complete unilateral cleft lip and palate and 15 controls with subjective normal nasal patency. Intervention: A transnasal series of three acoustic measurements of nasal volume was performed per nostril; measurements were taken both before and after decongestion with 0.3 mg xylom…

Adultmedicine.medical_specialtyDiagnostic methodsAdolescentNostrilBiophysicsNoseStatistics NonparametricUnilateral cleft palateNasal airwayXylometazolineCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineAcoustic Impedance TestsmedicineHumans030223 otorhinolaryngologybusiness.industryImidazolesAcoustics030206 dentistrySurgeryCleft PalateNasal Decongestantsmedicine.anatomical_structureOtorhinolaryngologyNasal CavityNasal ObstructionOral SurgeryAirwaybusinessmedicine.drugThe Cleft Palate-Craniofacial Journal
researchProduct